Dean Ferrera, DO
Interventional Cardiology · East Chicago, INNPI 1982727830
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Angiodynamics, Inc. at 32.9% of the total. Among interventional cardiology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,022 payments — averaging $176.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$59K
- Surmodics, Inc.$42K
- Medtronic$27K
- Shockwave Medical, Inc$15K
- Cardiovascular Systems Inc.$11K
- Abbott$3K
- plus $22K from 52 others
Across 17 payments — averaging $6923.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Surmodics, Inc.$78K
- Angiodynamics, Inc.$24K
- Philips North America LLC$16K
What the payments were for
- Consulting fees$76,92743%
- Speaking & faculty fees$38,76022%
- Travel & lodging$31,89318%
- Food & beverage$32,37018%
- Entertainment$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AlphaVac$53,839
- Pounce Thrombectomy System$40,835
- Pounce Venous Thrombectomy System$30,590
- Pounce Thrombectomy$26,845
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$14,917
- Diamondback Coronary$12,933
- HawkOne$12,347
- Sublime 014 Rx PTA Balloon Dilatation Catheter$9,479
- Sublime Microcatheter, 018, 200cm, Straight$8,465
- Diamondback Peripheral$8,354
- IN.PACT Admiral$7,767
- Pounce LP Thrombectomy$6,077
- Pounce XL Thrombectomy$5,175
- PROWL Registry$4,894
- AngioVac$3,537
- (9520) IGT Devices Undivided$1,880
- Sublime Radial Access 018 RX PTA Dilatation Catheter$1,014
- Sublime Radial Access Guide Sheath$1,014
- GUNTHER TULIP$1,000
- PRODIGY CATHETER$947
How this compares
$179,991 in reported general payments places this provider in the 95th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 291 | $366,413 |
| EliquisApixaban | 205 | $260,829 |
| XareltoRivaroxaban | 174 | $200,875 |
| Repatha SureclickEvolocumab | 164 | $128,410 |
| FarxigaDapagliflozin Propanediol | 100 | $108,587 |
| JardianceEmpagliflozin | 49 | $45,505 |
| BrilintaTicagrelor | 40 | $28,374 |
| Praluent PenAlirocumab | 16 | $13,661 |
| VerquvoVericiguat | 13 | $12,688 |
| Repatha PushtronexEvolocumab | 17 | $10,501 |
| OzempicSemaglutide | 12 | $10,442 |
| Metoprolol Succinate | 462 | $5,541 |
| Atorvastatin Calcium | 585 | $4,784 |
| ClopidogrelClopidogrel Bisulfate | 429 | $4,285 |
| Rosuvastatin Calcium | 251 | $4,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $1,438 | $366,413291 claims |
| PfizerEliquis | $235 | $260,829205 claims |
| Johnson & JohnsonXarelto | $646 | $200,875174 claims |
| AstraZenecaFarxiga, Brilinta | $467 | $136,961140 claims |
| Boehringer IngelheimJardiance | $254 | $45,50549 claims |
| MerckVerquvo | $516 | $12,68813 claims |
| Novo NordiskOzempic | $47 | $10,44212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in East Chicago
- Samer AbbasEast Chicago$395K
- Amit KakkarEast Chicago$20K
- Arif KhalilEast Chicago$15K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Muzammil MusaniFort Wayne$184K
- Shashidhar DivakaruniMunster$97K
- Jarrod FrizzellEvansville$86K
- Navneet LatherNoblesville$83K
- Michael BallIndianapolis$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.